Syapse

Precision cancer company Syapse is teaming with Seoul National University Hospital and Asian AWS partner Megazone

Pharmaceutical giant Roche has entered into a collaboration with Syapse to widen access to precision oncology technology and services.

Syapse has raised new venture capital to support expansion into community hospitals that want to start precision oncology programs.

Through the deal, Sylvester will have access to Syapse's precision medicine platform for cancer care.

The agreement lets Biotheranostics offer its CancerType ID and Breast Cancer Index genomic tests to customers through Syapse's software.

The two health systems have also joined the OPeN consortium and plan to share cancer patient data in support of the Cancer Moonshot Initiative. 

Within the consortium community healthcare systems can contribute and access each other's data on cancer patients' molecular profiles and treatment outcomes.

The consortium aims to share aggregated data between its members, enabling more cancer patients to benefit from high volume-based analytics.

The company is seeking partnerships that will enable it to offer its software to more users as part of larger, more integrated systems. 

Pages

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.